Jpmorgan Chase & CO Cellectis S.A. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Cellectis S.A. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 83 shares of CLLS stock, worth $151. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83
Previous 83
-0.0%
Holding current value
$151
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CLLS
# of Institutions
33Shares Held
11.2MCall Options Held
2.8KPut Options Held
17.9K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$8.4 Million0.35% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.36 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.62 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.62 Million0.0% of portfolio
-
Baillie Gifford & CO708KShares$1.29 Million0.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $82.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...